Metformin Shows Promise as Anti-Aging Drug Beyond Diabetes Treatment
Research reveals how the diabetes drug metformin may extend lifespan and healthspan through multiple molecular pathways.
20 articles
Research reveals how the diabetes drug metformin may extend lifespan and healthspan through multiple molecular pathways.
A 2025 review reveals how metformin's AMPK activation and mitochondrial effects may slow aging beyond its diabetes role.
A major review challenges the evidence behind metformin as a longevity drug, exposing methodological flaws in landmark studies.
New review maps metformin's complex pathways beyond diabetes, showing how it targets cancer and aging through AMPK, mTOR, and mitochondrial mechanisms.
A 2025 review reveals metformin's multi-pathway potential to slow arterial aging, reduce stiffness, and protect the heart.
A comprehensive review reveals metformin's polypharmacological mechanisms—from AMPK activation to gut microbiome remodeling—that may delay aging and enhance cancer immunotherapy.
A 2025 review reveals metformin's promising dermatological applications—from acne and psoriasis to wound healing and anti-aging effects.
Large randomized trial finds metformin doesn't slow placental aging, challenging its potential as anti-aging therapy during pregnancy.
A sweeping 2025 review traces metformin from its 1922 synthesis to its emerging roles in cancer, aging, and longevity.
Six-month trial examines whether metformin treatment can improve telomere length and longevity gene expression in prediabetic individuals.
Environmental factors in lab media can completely block metformin's lifespan benefits, while phenformin remains effective.
Novel drug delivery system combines metformin with bioactive compounds to combat bone aging and improve fracture repair in elderly patients.
A 1.6-million-person cohort study finds metformin neither prevents AMD development nor slows progression to advanced disease stages.
A 2025 narrative review examines metformin's benefits, risks, and sex-specific efficacy for prediabetic women navigating the menopausal transition.
A massive 860,000-patient multinational study finds metformin users face significantly lower delirium and mortality risk than those on DPP-4 inhibitors.
Small pilot study tests whether acarbose, a diabetes medication, can slow aging processes in healthy older adults through microbiome changes.
Peter Attia dissects the null results of the MET-PREVENT trial and what they reveal about the hard science of testing aging interventions.
Researchers reveal how chromatin fragments exit the nucleus via membrane trafficking and how metformin blocks this process to reduce age-related inflammation.
New C. elegans research reveals metformin interacts with mitochondrial and ER stress pathways in complex, context-dependent ways that alter longevity.
A landmark Nature study shows metformin can suppress the clonal advantage of DNMT3A-mutant blood stem cells, potentially preventing leukemia progression.